Sio Gene Therapies Inc. (SIOX) Stock is expected to grow
By Melanie Gerald October 9, 2021
Chardan Capital Markets raised the price target for the Sio Gene Therapies Inc. (NASDAQ:SIOX) stock to “a Buy”. The rating was released on July 12, 2021. The research report from H.C. Wainwright has reiterated the stock to Buy, with a price target set at $8. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on April 30, 2021, to Buy and set the price objective to $8. In their research brief published April 30, 2021, H.C. Wainwright analysts initiated the Sio Gene Therapies Inc. stock to Buy with a price target of $8.
Currently, 27.10 percent of Sio Gene Therapies Inc. shares are owned by insiders, and 30.40 percent are held by financial institutions. Cheruvu Pavan, the Chief Executive Officer at Sio Gene Therapies Inc. (SIOX) has bought 100,000 shares of firm on Mar 23 at a price of $2.48 against the total amount of $0.25 million. In another inside trade, Pande Atul, Director of Sio Gene Therapies Inc. (NASDAQ:SIOX) bought 10,000 shares of the firm on Nov 24 for a total worth of $23399.0 at a price of $2.34.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.